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**BACKGROUND:** The prevalence of bariatric surgery has increased dramatically over the last decade. Bariatric surgery leads to changes in gastrointestinal processes which ultimately affect oral drug bioavail­ability. Due to sparse clinical data, a "bottom-up" approach using *in vitro*-­*in vivo* extrapolation (IVIVE) in conjunction with systems pharmacology may be valuable in predicting trends in oral drug exposure post surgery.

**METHODS:** Virtual 'post bariatric surgery\' populations were created using the 'Advanced Dissolution Absorption and Metabolism (ADAM) model\' within the Simcyp Simulator (v10). Relevant *in vitro* data for cyclosporine and atorvastatin acid were incorporated into the model and simulations were run to mimic clinical investigations post bariatric surgery.

**RESULTS:** Simulated exposure to cyclosporine post surgery was reduced due to a lower fraction absorbed (fa) and the reduced peak plasma concentrations were consistent with the reported clinical ­observations. Simulated oral drug exposure of atorvastatin acid post Roux-en-Y gastric bypass surgery was also reflective of the observed data with indications of counteracting interplay between a reduced fa and increased fraction that escapes gut wall metabolism (FG). Observed exposure profiles with regards to t~max~ of atorvastatin acid post biliopancreatic diversion with duodenal switch were not fully recovered by simulations.

**CONCLUSION:** Trends in oral drug bioavailability pre- to post-bariatric surgery seem to be highly dependent on drug specific parameters such as affinity to CYP3A, solubility, permeability and surgery specific systems alterations. The potential of a systems pharmacology physiologically-based pharmacokinetic modeling approach was demonstrated, allowing a framework for optimization of oral drug therapy post bariatric surgery. Inability to fully recover observed changes in t~max~ in certain scenarios suggests that additional systems parameters, which are currently unknown, may play a vital role.
